Back to top

biotechs: Archive

Zacks Equity Research

VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints

The phase III THRIVE study evaluating Viridian's veligrotug for treating active thyroid eye disease meets all primary and secondary endpoints.

AMGNPositive Net Change KRYSNegative Net Change FULCNegative Net Change VRDNNegative Net Change

Zacks Equity Research

Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug

CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.

BMYPositive Net Change MRKPositive Net Change CRVSNegative Net Change FULCNegative Net Change

Zacks Equity Research

Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug

TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.

NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change TERNPositive Net Change

Zacks Equity Research

Relay Stock Soars on Upbeat Data From Breast Cancer Study

RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.

AZNPositive Net Change NVSPositive Net Change PFENegative Net Change RLAYNegative Net Change

Zacks Equity Research

RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study

The FDA removes the partial clinical holds on Rezolute's phase III study evaluating RZ358 for treating congenital hyperinsulinism.

ILMNPositive Net Change KRYSNegative Net Change RZLTNegative Net Change FULCNegative Net Change

Zacks Equity Research

Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug

The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and congenital disabilities.

NVSPositive Net Change CALTPositive Net Change TVTXNegative Net Change

Zacks Equity Research

Rocket Stock Down More Than 30% in Past Six Months: Here's Why

The recent regulatory setbacks related to RCKT's pipeline candidate, Kresladi (marnetegragene autotemcel) weigh heavily on the stock.

ILMNPositive Net Change RCKTNegative Net Change KRYSNegative Net Change FULCNegative Net Change

Zacks Equity Research

IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab

Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy options.

ILMNPositive Net Change KRYSNegative Net Change FULCNegative Net Change IMVTNegative Net Change

Zacks Equity Research

Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals

Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.

SNYPositive Net Change NVOPositive Net Change LLYNegative Net Change

Zacks Equity Research

Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient

HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin toxicities.

ILMNPositive Net Change KRYSNegative Net Change HOTHNegative Net Change FULCNegative Net Change

Zacks Equity Research

MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab

The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.

PFENegative Net Change MRNANegative Net Change KRYSNegative Net Change BNTXNegative Net Change

Neena Mishra

Why Biotech ETFs Are Beating the Market

: Biotech stocks are poised to benefit from lower rates

REGNNegative Net Change GILDPositive Net Change IBBNegative Net Change XBIPositive Net Change SBIOPositive Net Change

Zacks Equity Research

FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up

The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025. Shares rise.

JAZZNegative Net Change AXSMPositive Net Change KRYSNegative Net Change FULCNegative Net Change

Zacks Equity Research

BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years

BMRN divulges ambitious plans for business growth over the next 10 years. It expects yearly sales to grow at a mid-teen rate through 2034.

BMRNPositive Net Change ARCTNegative Net Change FULCNegative Net Change BVSPositive Net Change

Zacks Equity Research

Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug

The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.

REGNNegative Net Change RHHBYPositive Net Change MRKPositive Net Change BAYRYPositive Net Change

Zacks Equity Research

Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More

Novavax and Alnylam are in the spotlight following drug approval and regulatory updates, respectively.

ALNYNegative Net Change NVAXNegative Net Change PNo Net Change PCVXNegative Net Change ATHANegative Net Change

Kinjel Shah

Amgen Stock Rises Almost 20% in 6 Months: Buy, Sell or Hold?

AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested for now.

NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change

Zacks Equity Research

Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals

BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.

BIIBNegative Net Change ILMNPositive Net Change IONSPositive Net Change FULCNegative Net Change

Zacks Equity Research

Dyne Reports Mixed Data From DMD Study, Key Executives Step Down

DYN's shares plummet following mixed data from its ongoing DMD study. Senior executives of the company step down.

DYNNegative Net Change EXELNegative Net Change SRPTNegative Net Change KRYSNegative Net Change

Zacks Equity Research

Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug

DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.

BIIBNegative Net Change EXELNegative Net Change KRYSNegative Net Change DNLIPositive Net Change

Zacks Equity Research

ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal

Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

BIIBNegative Net Change LLYNegative Net Change ILMNPositive Net Change ATHANegative Net Change

Zacks Equity Research

Affimed Appoints New CEO, Shares Fall on Leadership Change

AFMD appoints Shawn M. Leland as the company's new chief executive officer. Stock falls on the news.

RHHBYPositive Net Change ILMNPositive Net Change AFMDNegative Net Change FULCNegative Net Change

Zacks Equity Research

Recursion Stock Down Despite Meeting Goal in Brain Disease Study

RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.

ILMNPositive Net Change KRYSNegative Net Change FULCNegative Net Change RXRXPositive Net Change

Zacks Equity Research

Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results

Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.

GSKNegative Net Change PFENegative Net Change MRKPositive Net Change PCVXNegative Net Change

Zacks Equity Research

Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures

Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.

ILMNPositive Net Change NBIXNegative Net Change XENENo Net Change PRAXPositive Net Change